Archives de pediatrie : organe officiel de la Societe francaise de pediatrie · 1997
[Congenital sideroblastic anemia in an infant].
Клинический случайАннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Goedseels J, De Caluwé J P, Alexander M
Аннотация
UNLABELLED: Sideroblastic anemia is rare in infants. When it occurs, it is generally hereditary and X-linked.
CASE REPORT: A microcytic anemia without iron deficiency was diagnosed in a 2-month old infant with probable acquired cytomegalic infection. Bone marrow examination disclosed ringed sideroblasts without cytomegalic inclusions. Treatment with pyridoxine was tried without effect and no other therapeutic trial was attempted. The child, now aged 5 years, remains well without blood transfusion.
CONCLUSION: Hereditary and acquired sideroblastic anemias may occur in infants and children. Whatever their cause might be, the evolution is unpredictable. The only successful treatment for the hereditary variant remains pyridoxine supplementation which brings relief in about one patient out of three. Efficiency and safety of other therapeutic regimens remain to be proven.
CASE REPORT: A microcytic anemia without iron deficiency was diagnosed in a 2-month old infant with probable acquired cytomegalic infection. Bone marrow examination disclosed ringed sideroblasts without cytomegalic inclusions. Treatment with pyridoxine was tried without effect and no other therapeutic trial was attempted. The child, now aged 5 years, remains well without blood transfusion.
CONCLUSION: Hereditary and acquired sideroblastic anemias may occur in infants and children. Whatever their cause might be, the evolution is unpredictable. The only successful treatment for the hereditary variant remains pyridoxine supplementation which brings relief in about one patient out of three. Efficiency and safety of other therapeutic regimens remain to be proven.